<!DOCTYPE html>
<html lang="en" dir="ltr">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="manifest" href="/manifest.json">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">

  <!-- SEO -->
  <title>Colorectal Cancer &mdash; Comprehensive Guide | StopMyCancer</title>
  <meta name="description" content="Evidence-based colorectal cancer guide: screening (colonoscopy, FIT, Cologuard), MSI/MMR biomarkers, FOLFOX chemotherapy, immunotherapy for MSI-H tumors, staging, surgery, and young-onset CRC. Plain language, real sources.">
  <meta name="keywords" content="colorectal cancer, colon cancer, rectal cancer, colonoscopy, screening, MSI, MMR, KRAS, BRAF, FOLFOX, FOLFIRI, immunotherapy, pembrolizumab, nivolumab, Lynch syndrome, young-onset colorectal cancer, staging, polyps, adenocarcinoma, CEA, biomarkers">
  <meta name="author" content="StopMyCancer">
  <link rel="canonical" href="https://stopmycancer.com/cancers/colorectal/">

  <!-- Open Graph -->
  <meta property="og:type" content="article">
  <meta property="og:title" content="Colorectal Cancer &mdash; Comprehensive Guide | StopMyCancer">
  <meta property="og:description" content="Plain-language colorectal cancer guide: screening, MSI testing, staging, chemotherapy, immunotherapy, and young-onset CRC. Evidence-based with real sources.">
  <meta property="og:url" content="https://stopmycancer.com/cancers/colorectal/">
  <meta property="og:site_name" content="StopMyCancer">
  <meta property="og:locale" content="en_US">
  <meta property="og:locale:alternate" content="es_ES">
  <meta property="og:locale:alternate" content="fr_FR">
  <meta property="og:image" content="https://images.unsplash.com/photo-1579684385127-1ef15d508118?w=1200&h=630&fit=crop&q=80">

  <!-- Twitter Card -->
  <meta name="twitter:card" content="summary_large_image">
  <meta name="twitter:title" content="Colorectal Cancer &mdash; Comprehensive Guide | StopMyCancer">
  <meta name="twitter:description" content="Plain-language colorectal cancer guide: screening, MSI testing, staging, chemotherapy, immunotherapy, and young-onset CRC. Evidence-based with real sources.">
  <meta name="twitter:image" content="https://images.unsplash.com/photo-1579684385127-1ef15d508118?w=1200&h=630&fit=crop&q=80">

  <!-- Schema.org MedicalCondition + BreadcrumbList -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalCondition",
    "name": "Colorectal Cancer",
    "alternateName": ["Colon Cancer", "Rectal Cancer", "CRC", "Bowel Cancer"],
    "description": "Colorectal cancer begins in the colon or rectum, usually starting as noncancerous polyps that can develop into cancer over time. It is the third most common cancer worldwide and is highly preventable through screening.",
    "url": "https://stopmycancer.com/cancers/colorectal/",
    "code": {
      "@type": "MedicalCode",
      "code": "C18-C20",
      "codingSystem": "ICD-10"
    },
    "associatedAnatomy": {
      "@type": "AnatomicalStructure",
      "name": "Colon and Rectum"
    },
    "riskFactor": [
      {"@type": "MedicalRiskFactor", "name": "Age over 45"},
      {"@type": "MedicalRiskFactor", "name": "Family history of colorectal cancer or polyps"},
      {"@type": "MedicalRiskFactor", "name": "Lynch syndrome (hereditary nonpolyposis colorectal cancer)"},
      {"@type": "MedicalRiskFactor", "name": "Inflammatory bowel disease (Crohn's disease, ulcerative colitis)"},
      {"@type": "MedicalRiskFactor", "name": "Diet high in red and processed meat"},
      {"@type": "MedicalRiskFactor", "name": "Obesity"},
      {"@type": "MedicalRiskFactor", "name": "Smoking"},
      {"@type": "MedicalRiskFactor", "name": "Heavy alcohol use"},
      {"@type": "MedicalRiskFactor", "name": "Sedentary lifestyle"},
      {"@type": "MedicalRiskFactor", "name": "Type 2 diabetes"}
    ],
    "signOrSymptom": [
      {"@type": "MedicalSignOrSymptom", "name": "Blood in stool (bright red or very dark)"},
      {"@type": "MedicalSignOrSymptom", "name": "Persistent change in bowel habits"},
      {"@type": "MedicalSignOrSymptom", "name": "Abdominal pain or cramping"},
      {"@type": "MedicalSignOrSymptom", "name": "Unexplained weight loss"},
      {"@type": "MedicalSignOrSymptom", "name": "Fatigue"},
      {"@type": "MedicalSignOrSymptom", "name": "Iron-deficiency anemia"}
    ],
    "possibleTreatment": [
      {"@type": "MedicalTherapy", "name": "Surgery (polypectomy, colectomy, low anterior resection, abdominoperineal resection)"},
      {"@type": "MedicalTherapy", "name": "Chemotherapy (FOLFOX, FOLFIRI, capecitabine)"},
      {"@type": "MedicalTherapy", "name": "Targeted therapy (bevacizumab, cetuximab, encorafenib)"},
      {"@type": "MedicalTherapy", "name": "Immunotherapy (pembrolizumab, nivolumab for MSI-H/dMMR tumors)"},
      {"@type": "MedicalTherapy", "name": "Radiation therapy (primarily for rectal cancer)"}
    ],
    "primaryPrevention": {
      "@type": "MedicalTherapy",
      "name": "Screening colonoscopy beginning at age 45 (average risk)"
    },
    "epidemiology": "Approximately 1.9 million new cases diagnosed globally per year. Third most common cancer worldwide. 5-year relative survival exceeds 90% when detected at Stage I.",
    "isPartOf": {
      "@type": "WebSite",
      "name": "StopMyCancer",
      "url": "https://stopmycancer.com"
    },
    "lastReviewed": "2025-01-15",
    "inLanguage": "en"
  }
  </script>
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
      {
        "@type": "ListItem",
        "position": 1,
        "name": "Home",
        "item": "https://stopmycancer.com/"
      },
      {
        "@type": "ListItem",
        "position": 2,
        "name": "Cancer Types",
        "item": "https://stopmycancer.com/cancers/"
      },
      {
        "@type": "ListItem",
        "position": 3,
        "name": "Colorectal Cancer",
        "item": "https://stopmycancer.com/cancers/colorectal/"
      }
    ]
  }
  </script>

  <!-- Hreflang for multilingual SEO -->
  <link rel="alternate" hreflang="en" href="https://stopmycancer.com/cancers/colorectal/">
  <link rel="alternate" hreflang="es" href="https://stopmycancer.com/es/cancers/colorectal/">
  <link rel="alternate" hreflang="fr" href="https://stopmycancer.com/fr/cancers/colorectal/">
  <link rel="alternate" hreflang="x-default" href="https://stopmycancer.com/cancers/colorectal/">

  <!-- Preconnect & Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
  <link rel="preconnect" href="https://images.unsplash.com">

  <!-- Stylesheet -->
  <link rel="stylesheet" href="/css/styles.css">

  <!-- Favicon -->
  <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><text y='.9em' font-size='90'>üõ°Ô∏è</text></svg>">
</head>
<body>

  <!-- Skip Link -->
  <a href="#main" class="skip-link">Skip to main content</a>

  <!-- Header -->
  <header class="header" role="banner">
    <div class="header__inner">
      <a href="/" class="header__logo" aria-label="StopMyCancer Home">
        <div class="header__logo-icon" aria-hidden="true">S</div>
        Stop<span>My</span>Cancer
      </a>

      <nav class="header__nav" role="navigation" aria-label="Main navigation">
        <a href="/cancers/" class="header__nav-link header__nav-link--active">Cancer Types</a>
        <a href="/navigate/" class="header__nav-link">Navigate</a>
        <a href="/stories/" class="header__nav-link">Stories</a>
        <a href="/access/" class="header__nav-link">Access &amp; Equity</a>
        <a href="/tools/pathology-translator" class="header__nav-link">Translator Tool</a>
        <a href="/about/" class="header__nav-link">About</a>
      </nav>

      <div class="header__actions">
        <div class="lang-switcher">
          <button class="lang-switcher__btn" aria-haspopup="true" aria-expanded="false" aria-label="Change language">
            <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"></circle><line x1="2" y1="12" x2="22" y2="12"></line><path d="M12 2a15.3 15.3 0 0 1 4 10 15.3 15.3 0 0 1-4 10 15.3 15.3 0 0 1-4-10 15.3 15.3 0 0 1 4-10z"></path></svg>
            EN
            <svg width="12" height="12" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M6 9l6 6 6-6"></path></svg>
          </button>
          <div class="lang-switcher__dropdown" role="menu">
            <a href="/cancers/colorectal/" class="lang-switcher__option lang-switcher__option--active" role="menuitem">English</a>
            <a href="/es/cancers/colorectal/" class="lang-switcher__option" role="menuitem">Espa&ntilde;ol</a>
            <a href="/fr/cancers/colorectal/" class="lang-switcher__option" role="menuitem">Fran&ccedil;ais</a>
          </div>
        </div>

        <button class="mobile-toggle" aria-label="Open menu" aria-expanded="false" aria-controls="mobile-nav">
          <span class="mobile-toggle__line"></span>
          <span class="mobile-toggle__line"></span>
          <span class="mobile-toggle__line"></span>
        </button>
      </div>
    </div>
  </header>

  <!-- Mobile Navigation -->
  <nav class="mobile-nav" id="mobile-nav" role="navigation" aria-label="Mobile navigation">
    <a href="/cancers/" class="mobile-nav__link">Cancer Types</a>
    <a href="/navigate/" class="mobile-nav__link">Navigate</a>
    <a href="/stories/" class="mobile-nav__link">Stories</a>
    <a href="/access/" class="mobile-nav__link">Access &amp; Equity</a>
    <a href="/tools/pathology-translator" class="mobile-nav__link">Pathology Translator</a>
    <a href="/about/" class="mobile-nav__link">About</a>
    <div class="mobile-nav__lang">
      <div class="mobile-nav__lang-title">Language</div>
      <div class="mobile-nav__lang-options">
        <a href="/cancers/colorectal/" class="mobile-nav__lang-btn mobile-nav__lang-btn--active">EN</a>
        <a href="/es/cancers/colorectal/" class="mobile-nav__lang-btn">ES</a>
        <a href="/fr/cancers/colorectal/" class="mobile-nav__lang-btn">FR</a>
      </div>
    </div>
  </nav>

  <main id="main">

    <!-- ==================== BREADCRUMB ==================== -->
    <section class="section" style="padding-top: var(--space-lg); padding-bottom: 0;">
      <div class="container">
        <nav class="breadcrumb fade-in" aria-label="Breadcrumb">
          <ol style="list-style: none; display: flex; flex-wrap: wrap; gap: 0.35rem; padding: 0; margin: 0; font-size: 0.9rem; color: var(--text-muted);">
            <li><a href="/" style="color: var(--primary); text-decoration: none;">Home</a></li>
            <li aria-hidden="true" style="margin: 0 0.15rem;">/</li>
            <li><a href="/cancers/" style="color: var(--primary); text-decoration: none;">Cancer Types</a></li>
            <li aria-hidden="true" style="margin: 0 0.15rem;">/</li>
            <li aria-current="page" style="color: var(--text-primary); font-weight: 600;">Colorectal Cancer</li>
          </ol>
        </nav>
      </div>
    </section>

    <!-- ==================== PAGE HEADER ==================== -->
    <section class="page-header">
      <div class="container">
        <div class="fade-in">
          <span class="page-header__label">Medical Encyclopedia</span>
          <h1 class="page-header__title">Colorectal Cancer</h1>
          <p class="page-header__desc">
            Rising in younger adults. Screening guidelines, MSI testing, and treatment explained in plain language.
          </p>
        </div>
        <div class="page-header__image fade-in" style="transition-delay: 0.15s;">
          <img src="https://images.unsplash.com/photo-1579684385127-1ef15d508118?w=1200&h=400&fit=crop&q=80" alt="Medical researcher in a clinical laboratory, representing evidence-based colorectal cancer research and screening" loading="eager" width="1200" height="400">
        </div>
      </div>
    </section>

    <!-- ==================== SAFETY NOTICE ==================== -->
    <section class="section" style="padding-top: 0; padding-bottom: var(--space-xl);">
      <div class="container">
        <div class="safety-banner fade-in">
          <svg class="safety-banner__icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M10.29 3.86L1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"></path><line x1="12" y1="9" x2="12" y2="13"></line><line x1="12" y1="17" x2="12.01" y2="17"></line></svg>
          <div class="safety-banner__text">
            <strong>Not medical advice.</strong> StopMyCancer is an educational resource. It does not diagnose, predict outcomes, or replace your care team. If you experience severe symptoms &mdash; sudden abdominal pain, rectal bleeding, difficulty breathing, high fever, or bowel obstruction &mdash; <strong>seek emergency medical care immediately</strong>.
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== QUICK OVERVIEW ==================== -->
    <section class="section section--alt" id="overview">
      <div class="container">
        <div class="section__header fade-in">
          <span class="section__label">At a Glance</span>
          <h2 class="section__title">Quick Overview</h2>
        </div>
        <div class="card-grid fade-in" style="max-width: 1100px; margin: 0 auto;">
          <div class="card">
            <div class="card__body" style="text-align: center; padding: var(--space-xl);">
              <div class="card__icon card__icon--primary" style="margin: 0 auto var(--space-sm); font-size: 28px; width: 56px; height: 56px;">
                <span aria-hidden="true">~1.9M</span>
              </div>
              <h3 class="card__title" style="font-size: 1rem;">New Cases Per Year</h3>
              <p class="card__desc">Approximately 1.9 million new colorectal cancer cases are diagnosed globally each year, making it the third most common cancer worldwide.</p>
              <p class="card__desc" style="font-size: 0.8rem; color: var(--text-muted); margin-top: var(--space-xs);">Source: <a href="#references">WHO; ACS</a></p>
            </div>
          </div>
          <div class="card">
            <div class="card__body" style="text-align: center; padding: var(--space-xl);">
              <div class="card__icon card__icon--secondary" style="margin: 0 auto var(--space-sm); font-size: 28px; width: 56px; height: 56px;">
                <span aria-hidden="true">3rd</span>
              </div>
              <h3 class="card__title" style="font-size: 1rem;">Most Common Cancer</h3>
              <p class="card__desc">Colorectal cancer ranks third in incidence among all cancers. Incidence rates are rising in adults under 50, a trend that has alarmed researchers.</p>
              <p class="card__desc" style="font-size: 0.8rem; color: var(--text-muted); margin-top: var(--space-xs);">Source: <a href="#references">Siegel et al., 2023</a></p>
            </div>
          </div>
          <div class="card">
            <div class="card__body" style="text-align: center; padding: var(--space-xl);">
              <div class="card__icon card__icon--accent" style="margin: 0 auto var(--space-sm); font-size: 28px; width: 56px; height: 56px;">
                <span aria-hidden="true">&gt;90%</span>
              </div>
              <h3 class="card__title" style="font-size: 1rem;">5-Year Survival at Stage I</h3>
              <p class="card__desc">When caught early (Stage I), the 5-year relative survival rate exceeds 90%. Colorectal cancer is highly preventable and treatable with screening.</p>
              <p class="card__desc" style="font-size: 0.8rem; color: var(--text-muted); margin-top: var(--space-xs);">Source: <a href="#references">NCI; ACS</a></p>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== WHAT IS COLORECTAL CANCER? ==================== -->
    <section class="section" id="what-is">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">Understanding the Basics</span>
          <h2 class="section__title" style="text-align: left;">What Is Colorectal Cancer?</h2>
          <div class="prose">
            <p>
              Colorectal cancer is cancer that starts in the <strong>colon</strong> (the large intestine) or the <strong>rectum</strong> (the last several inches of the colon, ending at the anus). Together, the colon and rectum make up the large bowel. When cancer develops in either location, it is collectively called <em>colorectal cancer</em> (CRC). If it starts specifically in the colon, you may hear it called <em>colon cancer</em>; if it starts in the rectum, <em>rectal cancer</em>.
            </p>
            <p>
              Most colorectal cancers begin as small, noncancerous growths on the inner lining of the colon or rectum called <strong>polyps</strong>. Not all polyps become cancer, but certain types &mdash; particularly <em>adenomatous polyps</em> (adenomas) &mdash; can develop into cancer over time. This process, known as the <strong>adenoma-to-carcinoma sequence</strong>, typically takes 10 to 15 years, which is why regular screening and polyp removal is so effective at preventing this disease.
            </p>
            <p>
              The colon absorbs water and nutrients from digested food; the rectum stores stool before it leaves the body. Cancers in these areas can disrupt these functions, cause bleeding, obstruct the bowel, and &mdash; if untreated &mdash; spread to lymph nodes and distant organs, most commonly the liver and lungs.
            </p>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== TYPES ==================== -->
    <section class="section section--alt" id="types">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">Histologic Types</span>
          <h2 class="section__title" style="text-align: left;">Types of Colorectal Cancer</h2>
          <div class="prose">
            <p>Not all colorectal cancers are the same. The type depends on which cells within the colon or rectum become cancerous.</p>

            <div class="card" style="margin-bottom: var(--space-lg);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Adenocarcinoma (95%+ of cases)</h3>
                <p class="card__desc">The overwhelming majority of colorectal cancers are adenocarcinomas &mdash; cancers that develop from the glandular cells lining the inside of the colon and rectum. When your doctor says "colorectal cancer," they almost always mean adenocarcinoma. Within this category are subtypes including <strong>mucinous adenocarcinoma</strong> (which produces mucus) and <strong>signet ring cell carcinoma</strong> (a rarer, often more aggressive form).</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-lg);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Carcinoid Tumors (Neuroendocrine Tumors)</h3>
                <p class="card__desc">These develop from hormone-producing cells in the intestinal lining. They tend to grow slowly and may not cause symptoms until they are advanced. Treatment and outlook differ significantly from adenocarcinoma.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-lg);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Gastrointestinal Stromal Tumors (GISTs)</h3>
                <p class="card__desc">GISTs arise from specialized cells in the wall of the GI tract called interstitial cells of Cajal. While more common in the stomach, they can occur in the colon or rectum. They are treated with targeted therapies such as imatinib rather than standard chemotherapy.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-lg);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Lymphoma</h3>
                <p class="card__desc">Lymphomas are cancers of the immune system that typically start in lymph nodes, but they can also begin in the colon or rectum. Primary colorectal lymphoma is uncommon and is staged and treated differently from adenocarcinoma.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-lg);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Squamous Cell Carcinoma (Rare)</h3>
                <p class="card__desc">Very rarely, cancers resembling squamous cell carcinomas (typically seen in the skin or esophagus) develop in the colon or rectum. These are treated differently from adenocarcinomas and are more commonly associated with the anal canal.</p>
              </div>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== RISK FACTORS ==================== -->
    <section class="section" id="risk-factors">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">Who Is Affected</span>
          <h2 class="section__title" style="text-align: left;">Risk Factors</h2>
          <div class="prose">
            <p>Having one or more risk factors does not mean you will get colorectal cancer, and some people develop it without any known risk factors. But understanding these factors helps you and your doctor make informed decisions about screening.</p>

            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Age.</strong> Risk increases significantly after age 45&ndash;50. However, incidence in adults under 50 is rising sharply.
                </div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Family history.</strong> Having a first-degree relative (parent, sibling, or child) with colorectal cancer approximately doubles your risk, especially if they were diagnosed before age 50.
                </div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Lynch syndrome (Hereditary Nonpolyposis Colorectal Cancer / HNPCC).</strong> This inherited condition, caused by mutations in mismatch repair (MMR) genes &mdash; MLH1, MSH2, MSH6, or PMS2 &mdash; dramatically increases lifetime risk of CRC (up to 70&ndash;80%). Screening should begin much earlier.
                </div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Familial Adenomatous Polyposis (FAP).</strong> This rare inherited condition causes hundreds to thousands of polyps in the colon, almost guaranteeing CRC without preventive surgery.
                </div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Inflammatory bowel disease (IBD).</strong> Long-standing ulcerative colitis or Crohn's disease of the colon increases risk. The longer you have had IBD and the more of the colon that is affected, the higher the risk.
                </div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Diet high in red and processed meat.</strong> Diets heavy in red meat (beef, pork, lamb) and processed meats (hot dogs, sausages, deli meats) are associated with increased risk. The WHO classifies processed meat as a Group 1 carcinogen.
                </div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Obesity.</strong> Being overweight or obese increases risk in both men and women, with a stronger association in men.
                </div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Smoking.</strong> Long-term smoking increases both the risk of developing colorectal cancer and the risk of dying from it.
                </div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Heavy alcohol use.</strong> Moderate to heavy drinking (3+ drinks per day) is linked to increased CRC risk.
                </div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Sedentary lifestyle.</strong> Regular physical activity has been consistently shown to lower CRC risk. People who are physically inactive face higher risk.
                </div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>
                  <strong>Type 2 diabetes.</strong> People with Type 2 diabetes have an increased risk of colorectal cancer, independent of obesity. Insulin resistance may play a role.
                </div>
              </li>
            </ul>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== SCREENING ==================== -->
    <section class="section section--alt" id="screening">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">Early Detection</span>
          <h2 class="section__title" style="text-align: left;">Screening</h2>
          <div class="prose">
            <p>
              Screening is the single most powerful tool against colorectal cancer. It can find polyps <em>before</em> they become cancer and detect cancer at an early, highly curable stage. In 2018, the <strong>American Cancer Society (ACS)</strong> lowered the recommended starting age for average-risk screening from 50 to <strong>45</strong> &mdash; a change later endorsed by the U.S. Preventive Services Task Force (USPSTF) in 2021. People at higher risk (family history, Lynch syndrome, IBD) should begin screening earlier and more frequently, as determined by their doctor.
            </p>

            <h3>Screening Methods</h3>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h4 class="card__title">Colonoscopy (Gold Standard)</h4>
                <p class="card__desc">A flexible camera (colonoscope) examines the entire colon and rectum. Polyps can be found <em>and</em> removed during the same procedure. If no polyps are found, repeat every 10 years for average-risk individuals. Requires bowel preparation the day before.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h4 class="card__title">FIT (Fecal Immunochemical Test)</h4>
                <p class="card__desc">A stool-based test that detects hidden blood &mdash; a potential sign of polyps or cancer. Done at home annually. Non-invasive and no bowel prep required. A positive result requires follow-up colonoscopy.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h4 class="card__title">FIT-DNA / Cologuard</h4>
                <p class="card__desc">Combines FIT with a test for altered DNA shed by cancerous or precancerous cells. Done at home every 3 years. Higher sensitivity than FIT alone but also more false positives. A positive result requires follow-up colonoscopy.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h4 class="card__title">CT Colonography (Virtual Colonoscopy)</h4>
                <p class="card__desc">Uses CT imaging to create detailed pictures of the colon. Less invasive than traditional colonoscopy but still requires bowel prep. If polyps are found, a standard colonoscopy is needed to remove them. Recommended every 5 years.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h4 class="card__title">High-Risk Screening</h4>
                <p class="card__desc">If you have Lynch syndrome, FAP, a strong family history, or a history of IBD, your doctor will likely recommend starting colonoscopy screening before age 45 &mdash; often at age 20&ndash;25 for Lynch syndrome or FAP, or 8&ndash;10 years after IBD diagnosis &mdash; and repeating it more frequently (every 1&ndash;2 years).</p>
              </div>
            </div>

            <p><strong>The bottom line:</strong> The best screening test is the one you actually complete. Talk to your doctor about which method is right for you, but do not skip screening altogether.</p>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== SYMPTOMS ==================== -->
    <section class="section" id="symptoms">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">Warning Signs</span>
          <h2 class="section__title" style="text-align: left;">Symptoms</h2>
          <div class="prose">
            <p>Many early colorectal cancers produce <strong>no symptoms at all</strong>. This is exactly why screening is so important. When symptoms do appear, they may include:</p>

            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Blood in the stool.</strong> This may appear bright red or make the stool very dark (tarry). Do not assume rectal bleeding is "just hemorrhoids" &mdash; get it checked.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Persistent change in bowel habits.</strong> Diarrhea, constipation, or narrowing of the stool that lasts more than a few days.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Abdominal pain or cramping.</strong> Persistent discomfort, bloating, fullness, or cramps that do not resolve.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Unexplained weight loss.</strong> Losing weight without trying can be a sign of many cancers, including CRC.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Fatigue and weakness.</strong> Persistent tiredness that does not improve with rest.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Iron-deficiency anemia.</strong> Chronic, slow blood loss from a tumor can deplete iron stores, sometimes discovered through routine bloodwork before other symptoms appear.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Feeling that the bowel does not empty completely.</strong> A sensation of incomplete evacuation, especially with rectal cancers.</div>
              </li>
            </ul>

            <div class="safety-banner" style="margin-top: var(--space-xl);">
              <svg class="safety-banner__icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M10.29 3.86L1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z"></path><line x1="12" y1="9" x2="12" y2="13"></line><line x1="12" y1="17" x2="12.01" y2="17"></line></svg>
              <div class="safety-banner__text">
                <strong>Many early colorectal cancers have no symptoms. Screening is key.</strong> If you are 45 or older and have not been screened, talk to your doctor. If you are under 45 and experiencing any of these symptoms persistently, do not let your age be a reason to delay evaluation.
              </div>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== DIAGNOSIS ==================== -->
    <section class="section section--alt" id="diagnosis">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">Finding Answers</span>
          <h2 class="section__title" style="text-align: left;">Diagnosis</h2>
          <div class="prose">
            <p>If screening or symptoms raise suspicion for colorectal cancer, several tests are used to confirm the diagnosis and determine how far the cancer has spread.</p>

            <h3>Core Diagnostic Tools</h3>

            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Colonoscopy with biopsy.</strong> The definitive diagnostic step. A colonoscopy allows the doctor to see the tumor directly and take tissue samples (biopsies). A pathologist examines these samples under a microscope to confirm cancer, determine the type, and assess grade.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>CT scan (chest, abdomen, pelvis).</strong> Used for staging &mdash; determining whether cancer has spread to lymph nodes, liver, lungs, or other organs.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>MRI.</strong> Particularly important for rectal cancer to assess how deeply the tumor invades the rectal wall and its relationship to surrounding structures. Helps plan surgery.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>CEA blood test (Carcinoembryonic Antigen).</strong> A tumor marker that can be elevated in colorectal cancer. Not used for screening or initial diagnosis, but used as a baseline before treatment and monitored over time to detect recurrence.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Molecular / biomarker testing.</strong> The tumor tissue is tested for MSI/MMR status, KRAS, NRAS, BRAF mutations, and sometimes HER2 amplification. These results guide treatment decisions, especially for advanced disease. (See the <a href="#biomarkers">Biomarkers</a> section below.)</div>
              </li>
            </ul>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== STAGING ==================== -->
    <section class="section" id="staging">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">How Far Has It Spread?</span>
          <h2 class="section__title" style="text-align: left;">Staging (TNM System)</h2>
          <div class="prose">
            <p>
              Staging describes how far colorectal cancer has spread. The <strong>TNM system</strong> &mdash; developed by the American Joint Committee on Cancer (AJCC) &mdash; evaluates three components: <strong>T</strong> (tumor size and depth of invasion), <strong>N</strong> (lymph node involvement), and <strong>M</strong> (distant metastasis). These combine into an overall stage from 0 to IV.
            </p>
            <p><em>Note: You may also see the historical <strong>Dukes staging system</strong> (A through D), which was widely used before TNM became the standard. Your pathology report will almost always use TNM.</em></p>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Stage 0 &mdash; Carcinoma In Situ</h3>
                <p class="card__desc">Abnormal cells are found only in the innermost lining (mucosa) of the colon or rectum. These cells have the potential to become cancer. Also called "intramucosal carcinoma." Typically treated with polypectomy alone during colonoscopy. Not yet technically an invasive cancer.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Stage I &mdash; Early, Localized</h3>
                <p class="card__desc">Cancer has grown through the mucosa into the submucosa (T1) or into the muscle layer of the colon/rectum wall (T2), but has <strong>not</strong> spread to lymph nodes or distant sites. Five-year survival exceeds 90%. Surgery alone is typically curative.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Stage II &mdash; Locally Advanced, Node-Negative</h3>
                <p class="card__desc">Cancer has grown through the wall of the colon or rectum (T3 or T4) but has <strong>not</strong> spread to lymph nodes. Stage IIA means the tumor has grown through the outermost layers (serosa). Stage IIB/IIC indicates the tumor has grown into or through the visceral peritoneum or has directly invaded other organs. Surgery is the primary treatment; adjuvant chemotherapy may be considered for high-risk Stage II cases (e.g., T4 tumors, poorly differentiated histology, MSS/MMR-proficient status, or fewer than 12 lymph nodes examined).</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Stage III &mdash; Lymph Node Involvement</h3>
                <p class="card__desc">Cancer has spread to nearby lymph nodes but <strong>not</strong> to distant sites. This is subdivided into IIIA, IIIB, and IIIC depending on how many lymph nodes are involved and the depth of tumor invasion. Treatment involves surgery followed by adjuvant chemotherapy (most commonly FOLFOX for about 3&ndash;6 months). Five-year survival ranges from approximately 50% to 80%, depending on the substage.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Stage IV &mdash; Metastatic</h3>
                <p class="card__desc">Cancer has spread to distant organs. Stage IVA means spread to one distant organ (most commonly the liver or lungs). Stage IVB involves two or more distant organs. Stage IVC means spread to the peritoneum (abdominal lining). Treatment is typically systemic (chemotherapy, targeted therapy, and/or immunotherapy). In some cases, surgery to remove limited metastases in the liver or lungs can be curative.</p>
              </div>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== BIOMARKERS ==================== -->
    <section class="section section--alt" id="biomarkers">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">Personalized Treatment</span>
          <h2 class="section__title" style="text-align: left;">Biomarkers &mdash; Why They Matter</h2>
          <div class="prose">
            <p>Biomarker testing (also called molecular testing or tumor profiling) analyzes specific features of your tumor's DNA and proteins. These results directly influence which treatments your oncologist recommends &mdash; especially in advanced disease. Here are the key biomarkers tested in colorectal cancer:</p>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">MSI / MMR Status</h3>
                <p class="card__desc"><strong>Microsatellite instability (MSI)</strong> and <strong>mismatch repair (MMR)</strong> testing look at how well a cell can correct errors in its DNA. Tumors are classified as <strong>MSI-H (high)</strong> / <strong>dMMR (deficient MMR)</strong> or <strong>MSS (microsatellite stable)</strong> / <strong>pMMR (proficient MMR)</strong>.</p>
                <p class="card__desc" style="margin-top: var(--space-sm);"><strong>Why it matters:</strong> MSI-H/dMMR tumors respond remarkably well to immunotherapy (checkpoint inhibitors like pembrolizumab and nivolumab). A landmark 2022 study in <em>The New England Journal of Medicine</em> by Cercek et al. showed that PD-1 blockade alone achieved a <strong>100% clinical complete response rate</strong> in a cohort of patients with dMMR locally advanced rectal cancer. MSI-H status also suggests possible Lynch syndrome, triggering genetic counseling referrals. About 15% of all colorectal cancers are MSI-H.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">KRAS and NRAS Mutations</h3>
                <p class="card__desc">KRAS and NRAS are genes in the RAS family. Mutations in these genes are found in approximately 40&ndash;50% of colorectal cancers (KRAS) and 3&ndash;5% (NRAS).</p>
                <p class="card__desc" style="margin-top: var(--space-sm);"><strong>Why it matters:</strong> Tumors with KRAS or NRAS mutations do <strong>not</strong> respond to anti-EGFR targeted therapies (cetuximab, panitumumab). Testing is essential before prescribing these drugs. Only patients with <em>RAS wild-type</em> (no mutations in KRAS or NRAS) tumors benefit from anti-EGFR therapy.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">BRAF V600E Mutation</h3>
                <p class="card__desc">The BRAF V600E mutation occurs in about 8&ndash;12% of colorectal cancers and is generally associated with a more aggressive disease course and poorer prognosis.</p>
                <p class="card__desc" style="margin-top: var(--space-sm);"><strong>Why it matters:</strong> BRAF V600E-mutated tumors are treated with a specific combination therapy: <strong>encorafenib</strong> (a BRAF inhibitor) plus <strong>cetuximab</strong> (an anti-EGFR antibody), a regimen shown to improve survival in the BEACON CRC trial. Testing for BRAF guides this treatment decision. BRAF V600E is also associated with MSI-H tumors in some cases, particularly in sporadic (non-hereditary) CRC.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">HER2 Amplification</h3>
                <p class="card__desc">HER2 (human epidermal growth factor receptor 2) overexpression or gene amplification occurs in about 2&ndash;6% of colorectal cancers.</p>
                <p class="card__desc" style="margin-top: var(--space-sm);"><strong>Why it matters:</strong> HER2-amplified, RAS wild-type colorectal cancers may respond to HER2-targeted therapies (trastuzumab-based combinations) that are already standard in HER2-positive breast and gastric cancers. Clinical trials continue to refine this approach.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">PD-L1 Expression</h3>
                <p class="card__desc">PD-L1 is a protein that can be found on tumor cells and helps cancer evade the immune system.</p>
                <p class="card__desc" style="margin-top: var(--space-sm);"><strong>Why it matters:</strong> While PD-L1 expression is a key biomarker in some other cancers (e.g., lung cancer), in colorectal cancer, MSI/MMR status is a more reliable predictor of immunotherapy response. PD-L1 testing may still be performed as part of comprehensive biomarker profiling.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h3 class="card__title">Tumor Mutational Burden (TMB)</h3>
                <p class="card__desc">TMB measures the total number of mutations found in a tumor's DNA. A high TMB (TMB-H) means the tumor has many mutations.</p>
                <p class="card__desc" style="margin-top: var(--space-sm);"><strong>Why it matters:</strong> TMB-H tumors may be more responsive to immunotherapy, as more mutations can mean more "targets" for the immune system to recognize. In colorectal cancer, TMB-H tends to correlate with MSI-H status but not always. Pembrolizumab is FDA-approved for TMB-H solid tumors regardless of cancer type.</p>
              </div>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== TREATMENT ==================== -->
    <section class="section" id="treatment">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">Treatment Options</span>
          <h2 class="section__title" style="text-align: left;">Treatment</h2>
          <div class="prose">
            <p>Treatment for colorectal cancer depends on the stage at diagnosis, the location (colon vs. rectum), biomarker results, and your overall health. Here is a detailed breakdown of the major treatment approaches.</p>

            <!-- Surgery -->
            <h3>Surgery</h3>
            <p>Surgery is the primary treatment for most colorectal cancers that have not spread widely. The type of surgery depends on the size, location, and stage of the tumor.</p>

            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Polypectomy.</strong> Removal of a polyp during colonoscopy. If cancer is contained within the polyp with clear margins, no further surgery may be needed.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Colectomy (partial or total).</strong> Removal of the section of colon containing the cancer, along with nearby lymph nodes. The remaining healthy parts of the colon are reconnected (anastomosis). This is the standard surgery for colon cancer. Can be done as open surgery or laparoscopically (minimally invasive).</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Low Anterior Resection (LAR).</strong> Used for rectal cancers in the upper portion of the rectum. The cancerous section is removed and the colon is reconnected to the remaining rectum, often preserving normal bowel function. A temporary diverting ostomy may be placed to allow healing.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Abdominoperineal Resection (APR).</strong> Used for rectal cancers very close to the anal sphincter. The rectum, anus, and surrounding tissue are removed, and a permanent colostomy is created. This is a more extensive surgery but sometimes necessary for low-lying tumors.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Metastasectomy (liver/lung resection).</strong> In select patients with limited metastases in the liver or lungs, surgery to remove these metastases can be curative. This is typically combined with chemotherapy and requires evaluation by a multidisciplinary team.</div>
              </li>
            </ul>

            <!-- Chemotherapy -->
            <h3>Chemotherapy</h3>
            <p>Chemotherapy uses drugs to kill cancer cells or stop them from growing. It is used in several settings for CRC:</p>
            <ul>
              <li><strong>Adjuvant chemotherapy</strong> &mdash; given after surgery (Stage III, and some high-risk Stage II) to destroy any remaining microscopic cancer cells and reduce recurrence risk.</li>
              <li><strong>Neoadjuvant chemotherapy</strong> &mdash; given before surgery, often for rectal cancer, to shrink the tumor and improve surgical outcomes.</li>
              <li><strong>Palliative chemotherapy</strong> &mdash; used in Stage IV to control disease growth, relieve symptoms, and extend survival.</li>
            </ul>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h4 class="card__title">Common Chemotherapy Regimens</h4>
                <ul class="checklist">
                  <li>
                    <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                    <div><strong>FOLFOX</strong> (5-FU + leucovorin + oxaliplatin) &mdash; the most common adjuvant regimen for Stage III CRC. Given every 2 weeks for 3&ndash;6 months.</div>
                  </li>
                  <li>
                    <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                    <div><strong>FOLFIRI</strong> (5-FU + leucovorin + irinotecan) &mdash; commonly used for metastatic CRC, either as first-line or after FOLFOX progression.</div>
                  </li>
                  <li>
                    <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                    <div><strong>Capecitabine (Xeloda)</strong> &mdash; an oral chemotherapy pill that converts to 5-FU in the body. Used alone for lower-risk adjuvant treatment or combined with oxaliplatin (CAPOX/XELOX).</div>
                  </li>
                </ul>
              </div>
            </div>

            <!-- Targeted Therapy -->
            <h3>Targeted Therapy</h3>
            <p>Targeted drugs attack specific molecules involved in cancer growth, often used in combination with chemotherapy for metastatic CRC.</p>

            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Bevacizumab (Avastin).</strong> An anti-VEGF antibody that blocks blood vessel growth to tumors. Used with chemotherapy for metastatic CRC regardless of RAS status.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Cetuximab (Erbitux) and Panitumumab (Vectibix).</strong> Anti-EGFR antibodies used <em>only</em> for RAS wild-type, left-sided tumors. Tumor sidedness matters: these drugs are most effective for cancers in the left colon (splenic flexure, descending, sigmoid) and rectum.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Encorafenib (Braftovi) + Cetuximab.</strong> Specifically for BRAF V600E-mutated CRC. This combination (from the BEACON CRC trial) improved overall survival compared to standard chemotherapy.</div>
              </li>
            </ul>

            <!-- Immunotherapy -->
            <h3>Immunotherapy</h3>
            <p>Immunotherapy helps the immune system recognize and attack cancer cells. In colorectal cancer, its role is defined by MSI/MMR status.</p>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h4 class="card__title">For MSI-H / dMMR Tumors</h4>
                <ul class="checklist">
                  <li>
                    <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                    <div><strong>Pembrolizumab (Keytruda).</strong> FDA-approved as first-line treatment for MSI-H/dMMR metastatic CRC. The KEYNOTE-177 trial showed pembrolizumab significantly improved progression-free survival compared to standard chemotherapy. Also now being studied in earlier stages.</div>
                  </li>
                  <li>
                    <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                    <div><strong>Nivolumab (Opdivo) +/- Ipilimumab (Yervoy).</strong> Another checkpoint inhibitor combination approved for MSI-H/dMMR metastatic CRC after prior chemotherapy.</div>
                  </li>
                </ul>
                <p class="card__desc" style="margin-top: var(--space-sm);">The Cercek et al. 2022 study in locally advanced dMMR rectal cancer (described in <a href="#biomarkers">Biomarkers</a>) represents a potential paradigm shift: immunotherapy alone may eliminate the need for surgery and radiation in select patients.</p>
              </div>
            </div>

            <div class="card" style="margin-bottom: var(--space-md);">
              <div class="card__body" style="padding: var(--space-lg);">
                <h4 class="card__title">For MSS / pMMR Tumors</h4>
                <p class="card__desc">The majority (~85%) of colorectal cancers are MSS/pMMR and currently do <strong>not</strong> respond well to standard immunotherapy. Active research is underway to find combinations that can overcome immunotherapy resistance in MSS tumors, including combinations with targeted therapies, radiation, and novel agents. Ask your oncologist about clinical trials.</p>
              </div>
            </div>

            <!-- Radiation -->
            <h3>Radiation Therapy</h3>
            <p>Radiation is primarily used for <strong>rectal cancer</strong>, not colon cancer.</p>
            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Neoadjuvant chemoradiation.</strong> Given before surgery for locally advanced rectal cancer (typically Stage II or III) to shrink the tumor and reduce recurrence. Standard approach: 5&ndash;6 weeks of radiation with concurrent capecitabine or 5-FU.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Short-course radiation.</strong> A more condensed approach (5 days of radiation) followed by chemotherapy, then surgery. Increasingly used as an alternative to long-course chemoradiation.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Palliative radiation.</strong> Used in metastatic settings to relieve symptoms such as pain, bleeding, or obstruction.</div>
              </li>
            </ul>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== YOUNG-ONSET CRC ==================== -->
    <section class="section section--alt" id="young-onset">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">An Emerging Crisis</span>
          <h2 class="section__title" style="text-align: left;">Young-Onset Colorectal Cancer</h2>
          <div class="prose">
            <p>
              One of the most alarming trends in oncology is the <strong>rising incidence of colorectal cancer in adults under 50</strong>. Between the mid-1990s and 2020, the incidence of CRC in people ages 20&ndash;49 has increased by approximately 1&ndash;2% per year in the United States and other high-income countries. In contrast, rates in adults over 50 have been declining, largely due to screening. The reasons for this increase remain under active investigation.
            </p>

            <h3>Key Concerns</h3>
            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Symptoms are often dismissed.</strong> Young adults who report rectal bleeding, changes in bowel habits, or abdominal pain may be told they are "too young for cancer" or have irritable bowel syndrome (IBS) or hemorrhoids. Diagnostic delays are common.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Later-stage diagnosis.</strong> Because screening historically did not start until age 50 (now 45), and because symptoms are often dismissed, young adults are more frequently diagnosed at Stage III or IV compared to older adults.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Distinct biology.</strong> Young-onset CRC may differ biologically from CRC in older adults, often occurring in the left side (rectum and sigmoid colon) and sometimes showing different molecular profiles.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Genetic testing is critical.</strong> All patients diagnosed with CRC under 50 should be assessed for hereditary cancer syndromes, particularly Lynch syndrome. The NCCN recommends universal MSI/MMR testing for all newly diagnosed colorectal cancers, regardless of age.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Unique psychosocial challenges.</strong> Young adults face distinct concerns: fertility preservation before treatment, career disruption, young children to care for, body image, and a sense of isolation ("no one my age understands").</div>
              </li>
            </ul>

            <h3>Advocacy</h3>
            <p>
              If you are a young adult experiencing persistent GI symptoms, <strong>advocate for a colonoscopy</strong>. Do not accept reassurance based solely on age. Advocacy organizations focused on young-onset CRC (such as the Colorectal Cancer Alliance, Fight Colorectal Cancer, and Never Too Young) provide resources, community, and support.
            </p>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== SIDE EFFECTS ==================== -->
    <section class="section" id="side-effects">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">What to Expect</span>
          <h2 class="section__title" style="text-align: left;">Side Effects &amp; Living With Treatment</h2>
          <div class="prose">
            <p>Treatment for colorectal cancer can cause side effects that range from manageable to significantly impactful on quality of life. Here is what to be aware of:</p>

            <h3>After Surgery</h3>
            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Bowel function changes.</strong> After partial colectomy, you may experience more frequent bowel movements, loose stools, urgency, or gas. These often improve over weeks to months as your body adjusts, but some changes may be permanent.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Ostomy care.</strong> If you have a colostomy or ileostomy (temporary or permanent), you will need to learn to care for the stoma and manage an ostomy pouch. Wound/ostomy care nurses (WOC nurses) are essential resources. Many people adapt well and live full, active lives with an ostomy.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Low anterior resection syndrome (LARS).</strong> After LAR for rectal cancer, you may experience urgency, frequency, incontinence, or clustering of bowel movements. LARS can significantly affect quality of life and should be discussed proactively with your surgical team.</div>
              </li>
            </ul>

            <h3>From Chemotherapy</h3>
            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Peripheral neuropathy (oxaliplatin).</strong> Oxaliplatin (used in FOLFOX) commonly causes tingling, numbness, or pain in the hands and feet, often triggered by cold. This can be temporary or, in some cases, long-lasting. Tell your oncologist about neuropathy symptoms early &mdash; dose adjustments may help prevent permanent damage.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Fatigue.</strong> Likely the most common side effect across all chemotherapy regimens. It can persist for weeks or months after treatment ends.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Nausea, diarrhea, mouth sores.</strong> Common with 5-FU-based regimens and irinotecan. Anti-nausea medications and dose adjustments can help manage these.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Hand-foot syndrome.</strong> Capecitabine can cause redness, swelling, and peeling on the palms and soles. Report early signs to your team.</div>
              </li>
            </ul>

            <h3>Fertility Considerations</h3>
            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Discuss fertility before treatment begins.</strong> Chemotherapy and pelvic radiation can impair fertility in both men and women. If preserving fertility is important to you, ask for a referral to a reproductive specialist <em>before</em> starting treatment. Options include sperm banking, egg/embryo freezing, and ovarian tissue cryopreservation.</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div><strong>Pelvic radiation and sexual health.</strong> Radiation for rectal cancer can affect sexual function in both men (erectile dysfunction) and women (vaginal changes, pain). These are legitimate medical concerns &mdash; discuss them openly with your care team.</div>
              </li>
            </ul>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== QUESTIONS TO ASK ==================== -->
    <section class="section section--alt" id="questions">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">Be Prepared</span>
          <h2 class="section__title" style="text-align: left;">Questions to Ask Your Doctor</h2>
          <div class="prose">
            <p>Bring these questions to your appointments. You have the right to understand your diagnosis and treatment plan.</p>

            <h3>At Diagnosis</h3>
            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>What is my exact diagnosis, including the type, grade, and stage?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>Has my tumor been tested for MSI/MMR status, KRAS, NRAS, and BRAF?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>What imaging or additional tests do I need before treatment begins?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>Should I be referred to a genetic counselor based on my age or family history?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>Is a second opinion recommended, and will you support me getting one?</div>
              </li>
            </ul>

            <h3>About Screening</h3>
            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>When should I start colorectal cancer screening, given my age and risk factors?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>Which screening method do you recommend for me &mdash; colonoscopy, FIT, or Cologuard?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>How often should I be screened if I have a family history of CRC or polyps?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>Should my family members get screened earlier because of my diagnosis?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>What happens if my FIT or Cologuard test comes back positive?</div>
              </li>
            </ul>

            <h3>About Treatment</h3>
            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>What are my treatment options, and what do you recommend and why?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>Will I need chemotherapy after surgery? For how long?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>What are the expected side effects, and how will we manage them?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>Is there a clinical trial I should consider for my specific situation?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>Will I need an ostomy? If so, will it be temporary or permanent?</div>
              </li>
            </ul>

            <h3>About Genetic Testing</h3>
            <ul class="checklist">
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>Should I have genetic testing for Lynch syndrome or other hereditary cancer syndromes?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>What does my MSI/MMR result mean for treatment and for my family?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>If I have Lynch syndrome, what cancers am I at increased risk for beyond CRC?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>Should my children or siblings see a genetic counselor?</div>
              </li>
              <li>
                <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polyline points="20 6 9 17 4 12"></polyline></svg>
                <div>How does my KRAS, NRAS, or BRAF status affect my treatment options?</div>
              </li>
            </ul>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== SOURCES & REFERENCES ==================== -->
    <section class="section" id="references">
      <div class="container" style="max-width: 800px;">
        <div class="fade-in">
          <span class="section__label">Evidence Base</span>
          <h2 class="section__title" style="text-align: left;">Sources &amp; References</h2>
          <div class="prose">
            <p>Every claim on this page is grounded in established medical literature and clinical guidelines. This page is not a substitute for professional medical advice.</p>

            <ol style="line-height: 1.9; font-size: 0.95rem;">
              <li>
                World Health Organization (WHO). "Colorectal Cancer Fact Sheet." <a href="https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer" target="_blank" rel="noopener noreferrer">who.int</a>
              </li>
              <li>
                American Cancer Society. "Colorectal Cancer." <a href="https://www.cancer.org/cancer/colon-rectal-cancer.html" target="_blank" rel="noopener noreferrer">cancer.org</a>
              </li>
              <li>
                American Cancer Society. "Colorectal Cancer Screening Guidelines." Updated 2018. Recommended screening beginning at age 45 for average-risk adults. <a href="https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html" target="_blank" rel="noopener noreferrer">cancer.org</a>
              </li>
              <li>
                National Cancer Institute. "Colon Cancer Treatment (PDQ) &mdash; Health Professional Version." <a href="https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq" target="_blank" rel="noopener noreferrer">cancer.gov</a>
              </li>
              <li>
                National Comprehensive Cancer Network (NCCN). "NCCN Clinical Practice Guidelines in Oncology: Colon Cancer / Rectal Cancer." <a href="https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf" target="_blank" rel="noopener noreferrer">nccn.org</a>
              </li>
              <li>
                Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. "Colorectal cancer statistics, 2023." <em>CA: A Cancer Journal for Clinicians</em>. 2023;73(3):233&ndash;254. <a href="https://doi.org/10.3322/caac.21772" target="_blank" rel="noopener noreferrer">doi.org/10.3322/caac.21772</a>
              </li>
              <li>
                Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. "Colorectal cancer." <em>The Lancet</em>. 2019;394(10207):1467&ndash;1480. <a href="https://doi.org/10.1016/S0140-6736(19)32319-0" target="_blank" rel="noopener noreferrer">doi.org/10.1016/S0140-6736(19)32319-0</a>
              </li>
              <li>
                Cercek A, Lumish M, Sinopoli J, et al. "PD-1 Blockade in Mismatch Repair&ndash;Deficient, Locally Advanced Rectal Cancer." <em>The New England Journal of Medicine</em>. 2022;386(25):2363&ndash;2376. <a href="https://doi.org/10.1056/NEJMoa2201445" target="_blank" rel="noopener noreferrer">doi.org/10.1056/NEJMoa2201445</a>
              </li>
            </ol>

            <p style="margin-top: var(--space-xl); padding: var(--space-md); background: var(--bg-secondary); border-radius: var(--radius-md); font-size: 0.9rem; color: var(--text-muted);">
              <strong>Last reviewed: January 2025.</strong> StopMyCancer reviews and updates its content regularly as new evidence emerges. If you notice information that appears outdated, please contact us.
            </p>
          </div>
        </div>
      </div>
    </section>

    <!-- ==================== CTA BANNER ==================== -->
    <section class="section section--alt">
      <div class="container">
        <div class="cta-banner fade-in">
          <h2>Understand Your Pathology Report</h2>
          <p>Paste your colorectal cancer pathology report and get plain-language explanations of staging, biomarkers, MSI status, and more. Free, private, and evidence-based.</p>
          <a href="/tools/pathology-translator" class="btn btn--accent btn--lg">
            <svg width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z"></path><polyline points="14 2 14 8 20 8"></polyline><line x1="16" y1="13" x2="8" y2="13"></line><line x1="16" y1="17" x2="8" y2="17"></line></svg>
            Translate My Pathology Report
          </a>
        </div>
      </div>
    </section>

  </main>

  <!-- ==================== FOOTER ==================== -->
  <footer class="footer" role="contentinfo">
    <div class="container">
      <div class="footer__grid">
        <div class="footer__brand">
          <div class="footer__logo">Stop<span>My</span>Cancer</div>
          <p class="footer__tagline">Your cancer. Explained. Supported. Navigated. A clinically-grounded, plain-language cancer guide. Free, global, and female-first.</p>
        </div>
        <div>
          <h4 class="footer__col-title">Learn</h4>
          <a href="/cancers/" class="footer__link">Cancer Types</a>
          <a href="/navigate/" class="footer__link">Navigation Guides</a>
          <a href="/stories/" class="footer__link">Stories</a>
          <a href="/access/" class="footer__link">Access &amp; Equity</a>
        </div>
        <div>
          <h4 class="footer__col-title">Tools</h4>
          <a href="/tools/pathology-translator" class="footer__link">Pathology Translator</a>
          <a href="/navigate/questions-to-ask" class="footer__link">Questions to Ask</a>
          <a href="/navigate/second-opinion" class="footer__link">Second Opinion Guide</a>
        </div>
        <div>
          <h4 class="footer__col-title">About</h4>
          <a href="/about/" class="footer__link">Our Mission</a>
          <a href="/about/#evidence" class="footer__link">Evidence Standards</a>
          <a href="/about/#safety" class="footer__link">Safety Framework</a>
        </div>
      </div>
      <div class="footer__bottom">
        <p class="footer__copyright">&copy; 2025 StopMyCancer.com. Not medical advice. Educational resource only. Always consult your care team.</p>
        <div class="footer__legal">
          <a href="/es/" class="footer__legal-link">Espa&ntilde;ol</a>
          <a href="/fr/" class="footer__legal-link">Fran&ccedil;ais</a>
        </div>
      </div>
    </div>
  </footer>

  <!-- Scripts -->
  <script src="/js/main.js"></script>
</body>
</html>
